NYMX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 jul 2023 @ 22:00):

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally...

Stats
Dagens volum	881 574
Gjennomsnittsvolum	134 777
Markedsverdi	18.24M
EPS	$0.0100 ( 2023-08-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.161 (16.48%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2023-04-25	Robinson James George	Buy	40 000	Common Stock
2022-05-02	Robinson James George	Buy	1 151 515	Warrant
2021-04-22	Robinson James George	Buy	200	Common Stock

INSIDER POWER
100.00
Last 100 transactions
Buy: 1 546 252 \| Sell: 0

Volum Korrelasjon

Lang: -0.08 (neutral)

Kort: -0.02 (neutral)

Signal:(67.127) Neutral

Nymox Pharmaceutical Corp Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Nymox Pharmaceutical Corp Korrelasjon - Valuta/Råvare

-0.25
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

-0.04
( neutral )

0.38
( neutral )

Nymox Pharmaceutical Corp Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.0735

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.0735

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.150

FY	2020
Omsetning:	$5 000.00
Bruttogevinst:	$1 000.00 (20.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.